when hma fails: newer therapeutic agents for mds
Published 8 years ago • 236 plays • Length 24:10Download video MP4
Download video MP3
Similar videos
-
22:13
how to approach hma failure?
-
3:32
mds: managing hma failure
-
22:41
new opportunities in experimental therapeutics in mds
-
18:29
aml treatment challenges who, when, and how
-
1:41
pursuing combination therapies to overcome single-agent hma failure in patients with mds
-
21:55
a unified approach to lower risk mds: standard and emerging therapies
-
25:20
promise and pitfalls in molecular testing in the diagnosis of mds
-
3:25
"misconceptions of sudden death" by dr. ma, cardiologist & electrophysiologist at island hospital
-
6:15
new law gives patients right to refuse end-of-life care
-
50:45
2017 wmif | heart failure's therapeutic mandate
-
23:20
therapy for “early mf”: pros and cons
-
19:11
novel agents and combination therapies in myelofibrosis
-
19:12
an approach to diagnosis and staging of mds: from morphology to genetics
-
1:00:13
treating mds after hypomethylating agent failure
-
27:16
diagnosis and therapy of cmml in 2015
-
16:55
mutational profiling in patients with mds: ready for every-day use in the clinic?
-
25:10
management of lower-risk mds without del5q and refractory to esas
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
13:24
mutation-based risk stratification approaches in myelofibrosis: any real clinical utility?
-
25:52
management of cmml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml